Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma

Correlations with clinical parameters and survival

Seok Jin Kim, In Keun Choi, Kyong Hwa Park, So Young Yoon, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Platelets have been reported to act as transporters of tumor-originated vascular endothelial growth factor (VEGF), contributing to tumor angiogenesis and progression. Serum VEGF per platelet count, as an indirect theoretical estimate of VEGF in platelets, may predict the malignant potential of tumors. However, its prognostic significance is still unclear in hepatocellular carcinoma (HCC), a highly vascular tumor. Methods: Serum VEGF was measured by enzyme-linked immunosorbent assay. We compared serum VEGF, platelet count and serum VEGF per platelet count in 52 HCC patients, 26 liver cirrhosis patients and 30 healthy controls. The relation of serum VEGF per platelet count with clinicopathologic variables of HCC patients and the prognostic significance were investigated. Results: Serum VEGF per platelet count in HCC patients was higher than in liver cirrhosis patients and healthy controls (P< 0.01). There was a statistically significant correlation between serum VEGF and platelet count in HCC patients (r = 0.751, P < 0.01). Serum VEGF per platelet count was higher in patients with advanced stage and portal vein thrombosis (P < 0.01). Patients with high serum VEGF per platelet count (>1.4 pg/106) showed poor response to treatment and shorter overall survival (P < 0.01). Serum VEGF per platelet count was an independent prognostic factor with the presence of portal vein thrombosis (P < 0.01). Conclusions: Serum VEGF per platelet count could be a feasible prognostic indicator during the follow-up of patients with HCC.

Original languageEnglish
Pages (from-to)184-190
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume34
Issue number4
DOIs
Publication statusPublished - 2004 Apr 1

Fingerprint

Platelet Count
Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Survival
Serum
Liver Cirrhosis
Neoplasms
Blood Platelets
Portal Vein
Blood Vessels
Thrombosis
Enzyme-Linked Immunosorbent Assay

Keywords

  • Hepatocellular carcinoma (HCC)
  • Platelet count
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology

Cite this

@article{26a5a501754a4883ba17a0866312a6d5,
title = "Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma: Correlations with clinical parameters and survival",
abstract = "Background: Platelets have been reported to act as transporters of tumor-originated vascular endothelial growth factor (VEGF), contributing to tumor angiogenesis and progression. Serum VEGF per platelet count, as an indirect theoretical estimate of VEGF in platelets, may predict the malignant potential of tumors. However, its prognostic significance is still unclear in hepatocellular carcinoma (HCC), a highly vascular tumor. Methods: Serum VEGF was measured by enzyme-linked immunosorbent assay. We compared serum VEGF, platelet count and serum VEGF per platelet count in 52 HCC patients, 26 liver cirrhosis patients and 30 healthy controls. The relation of serum VEGF per platelet count with clinicopathologic variables of HCC patients and the prognostic significance were investigated. Results: Serum VEGF per platelet count in HCC patients was higher than in liver cirrhosis patients and healthy controls (P< 0.01). There was a statistically significant correlation between serum VEGF and platelet count in HCC patients (r = 0.751, P < 0.01). Serum VEGF per platelet count was higher in patients with advanced stage and portal vein thrombosis (P < 0.01). Patients with high serum VEGF per platelet count (>1.4 pg/106) showed poor response to treatment and shorter overall survival (P < 0.01). Serum VEGF per platelet count was an independent prognostic factor with the presence of portal vein thrombosis (P < 0.01). Conclusions: Serum VEGF per platelet count could be a feasible prognostic indicator during the follow-up of patients with HCC.",
keywords = "Hepatocellular carcinoma (HCC), Platelet count, Vascular endothelial growth factor",
author = "Kim, {Seok Jin} and Choi, {In Keun} and Park, {Kyong Hwa} and Yoon, {So Young} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Choi, {Chul Won} and Kim, {Byung Soo} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk}",
year = "2004",
month = "4",
day = "1",
doi = "10.1093/jjco/hyh039",
language = "English",
volume = "34",
pages = "184--190",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor per platelet count in hepatocellular carcinoma

T2 - Correlations with clinical parameters and survival

AU - Kim, Seok Jin

AU - Choi, In Keun

AU - Park, Kyong Hwa

AU - Yoon, So Young

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Choi, Chul Won

AU - Kim, Byung Soo

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

PY - 2004/4/1

Y1 - 2004/4/1

N2 - Background: Platelets have been reported to act as transporters of tumor-originated vascular endothelial growth factor (VEGF), contributing to tumor angiogenesis and progression. Serum VEGF per platelet count, as an indirect theoretical estimate of VEGF in platelets, may predict the malignant potential of tumors. However, its prognostic significance is still unclear in hepatocellular carcinoma (HCC), a highly vascular tumor. Methods: Serum VEGF was measured by enzyme-linked immunosorbent assay. We compared serum VEGF, platelet count and serum VEGF per platelet count in 52 HCC patients, 26 liver cirrhosis patients and 30 healthy controls. The relation of serum VEGF per platelet count with clinicopathologic variables of HCC patients and the prognostic significance were investigated. Results: Serum VEGF per platelet count in HCC patients was higher than in liver cirrhosis patients and healthy controls (P< 0.01). There was a statistically significant correlation between serum VEGF and platelet count in HCC patients (r = 0.751, P < 0.01). Serum VEGF per platelet count was higher in patients with advanced stage and portal vein thrombosis (P < 0.01). Patients with high serum VEGF per platelet count (>1.4 pg/106) showed poor response to treatment and shorter overall survival (P < 0.01). Serum VEGF per platelet count was an independent prognostic factor with the presence of portal vein thrombosis (P < 0.01). Conclusions: Serum VEGF per platelet count could be a feasible prognostic indicator during the follow-up of patients with HCC.

AB - Background: Platelets have been reported to act as transporters of tumor-originated vascular endothelial growth factor (VEGF), contributing to tumor angiogenesis and progression. Serum VEGF per platelet count, as an indirect theoretical estimate of VEGF in platelets, may predict the malignant potential of tumors. However, its prognostic significance is still unclear in hepatocellular carcinoma (HCC), a highly vascular tumor. Methods: Serum VEGF was measured by enzyme-linked immunosorbent assay. We compared serum VEGF, platelet count and serum VEGF per platelet count in 52 HCC patients, 26 liver cirrhosis patients and 30 healthy controls. The relation of serum VEGF per platelet count with clinicopathologic variables of HCC patients and the prognostic significance were investigated. Results: Serum VEGF per platelet count in HCC patients was higher than in liver cirrhosis patients and healthy controls (P< 0.01). There was a statistically significant correlation between serum VEGF and platelet count in HCC patients (r = 0.751, P < 0.01). Serum VEGF per platelet count was higher in patients with advanced stage and portal vein thrombosis (P < 0.01). Patients with high serum VEGF per platelet count (>1.4 pg/106) showed poor response to treatment and shorter overall survival (P < 0.01). Serum VEGF per platelet count was an independent prognostic factor with the presence of portal vein thrombosis (P < 0.01). Conclusions: Serum VEGF per platelet count could be a feasible prognostic indicator during the follow-up of patients with HCC.

KW - Hepatocellular carcinoma (HCC)

KW - Platelet count

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=18344402517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344402517&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyh039

DO - 10.1093/jjco/hyh039

M3 - Article

VL - 34

SP - 184

EP - 190

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 4

ER -